Dasatinib treatment long-term results among
imatinib-resistant/intolerant patients with chronic phase
chronic myeloid leukemia are favorable in daily clinical
practice

J 2021

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, Lukas STEJSKAL, Tereza NEČASOVÁ et. al.

Basic information

Original name

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

Authors

ŽÁČKOVÁ, Daniela (203 Czech Republic, belonging to the institution), Hana KLAMOVA (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Tereza NEČASOVÁ (203 Czech Republic), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Dana SRBOVA (203 Czech Republic), Jaroslava VOGLOVA (203 Czech Republic), Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution), Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), Tomáš HORŇÁK (703 Slovakia, belonging to the institution), Jana BARANOVÁ (703 Slovakia), Jiřina PROCHÁZKOVÁ (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

LEUKEMIA & LYMPHOMA, LONDON, TAYLOR & FRANCIS, 2021, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.996

RIV identification code

RIV/00216224:14110/21:00120810

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/10428194.2020.1827242

UT WoS

000575624800001

Keywords in English

Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice

Abstract

V originále

To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.

Links

MUNI/A/1395/2019, interní kód MU

Name: Nové přístupy ve výzkumu, diagnostice a terapii hematologických malignit VII (Acronym: VýDiTeHeMa VII)

Investor: Masaryk University, Category A

90128, large research infrastructures

Name: CZECRIN III

Citovat

ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, Lukas STEJSKAL, Tereza NEČASOVÁ, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ, Dana SRBOVA, Jaroslava VOGLOVA, Petra ČIČÁTKOVÁ, Zuzana ŠUSTKOVÁ, Tomáš HORŇÁK, Jana BARANOVÁ, Jiřina PROCHÁZKOVÁ and Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2021, vol. 62, No 1, p. 194-202. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2020.1827242.

@article{1695400,
   author = {Žáčková, Daniela and Klamova, Hana and Belohlavkova, Petra and Stejskal, Lukas and Nečasová, Tereza and Semerád, Lukáš and Weinbergerová, Barbora and Srbova, Dana and Voglova, Jaroslava and Čičátková, Petra and Šustková, Zuzana and Horňák, Tomáš and Baranová, Jana and Procházková, Jiřina and Mayer, Jiří},
   article_location = {LONDON},
   article_number = {1},
   doi = {http://dx.doi.org/10.1080/10428194.2020.1827242},
   keywords = {Chronic myeloid leukemia; chronic phase; imatinib; dasatinib; second line; daily clinical practice},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice},
   url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242},
   volume = {62},
   year = {2021}
}

TY  - JOUR
ID  - 1695400
AU  - Žáčková, Daniela - Klamova, Hana - Belohlavkova, Petra - Stejskal, Lukas - Nečasová, Tereza - Semerád, Lukáš - Weinbergerová, Barbora - Srbova, Dana - Voglova, Jaroslava - Čičátková, Petra - Šustková, Zuzana - Horňák, Tomáš - Baranová, Jana - Procházková, Jiřina - Mayer, Jiří
PY  - 2021
TI  - Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice
JF  - LEUKEMIA & LYMPHOMA
VL  - 62
IS  - 1
SP  - 194-202
EP  - 194-202
PB  - TAYLOR & FRANCIS
SN  - 10428194
KW  - Chronic myeloid leukemia
KW  - chronic phase
KW  - imatinib
KW  - dasatinib
KW  - second line
KW  - daily clinical practice
UR  - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
L2  - https://www.tandfonline.com/doi/full/10.1080/10428194.2020.1827242
N2  - To evaluate long-term real-life results of dasatinib therapy among chronic phase chronic myeloid leukemia patients resistant or intolerant to imatinib, we retrospectively analyzed data of 118 patients treated in centers participating in the database INFINITY. With median follow-up of 37 months, estimated 5-year cumulative incidences of complete cytogenetic and major molecular responses were 78% and 68%, respectively. The estimated 5-year probability of overall survival (OS) and event-free survival (EFS) were 86% and 83%, respectively. Both OS and EFS were significantly improved among patients withBCR-ABL1transcript level <= 10% at 3 months. Dasatinib toxicity was tolerable however persistent in almost half our patients, even after years of therapy. Pleural effusion occurred in 29% of patients and was responsible for 30% of dasatinib discontinuations. Our results confirmed very good efficacy and acceptable toxicity of dasatinib in second line setting and support the evidence and importance of high-quality real-life CML patient management.
ER  -

ŽÁČKOVÁ, Daniela, Hana KLAMOVA, Petra BELOHLAVKOVA, Lukas STEJSKAL, Tereza NEČASOVÁ, Lukáš SEMERÁD, Barbora WEINBERGEROVÁ, Dana SRBOVA, Jaroslava VOGLOVA, Petra ČIČÁTKOVÁ, Zuzana ŠUSTKOVÁ, Tomáš HORŇÁK, Jana BARANOVÁ, Jiřina PROCHÁZKOVÁ and Jiří MAYER. Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: TAYLOR \&{} FRANCIS, 2021, vol.~62, No~1, p.~194-202. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2020.1827242.

Detailed Information on Publication Record